MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s40119-025-00442-4

Медицинская библиотека · Cardiology and therapy · 2025

Study Design and Baseline Characteristics of the VERINA Study: Phase IV Evidence of Vericiguat for Worsening Heart Failure Management.

Abdulakutty Jabir, Abhyankar Atul, Seth Sandeep, Sharma Kamal, Aggarwal Rakesh Kumar, Bhalani Nirav, Vijan Vinod, Bansal Sandeep, Jain Rajendra Kumar Premchand, Banerjee Suvro, Chopra V K, Oomman Abraham, Kahale Pravin, Sodhi Priyanka, Gawde Ashish

СтатьяПеревод в очереди

Аннотация

INTRODUCTION

Patients with heart failure with reduced ejection fraction (HFrEF) experience higher rates of in-hospital and all-cause mortality. On the basis of the VERINA trial, vericiguat is indicated for patients who have had a worsening heart failure (WHF) event despite optimal heart failure (HF) therapy, or for those with tolerability concerns.

METHODS

This multicenter, prospective, single-arm, non-randomized, real-world, descriptive study assessed the efficacy and safety of vericiguat in Indian patients aged ≥18 years with chronic HFrEF who were vericiguat-naïve and started treatment as per the local label. This analysis is based on interim data and the final results may differ. The main endpoint was a composite of cardiovascular (CV) death or first HF hospitalization. Secondary endpoints included each component of the primary outcome, all-cause death, and safety. Dose-titration parameters, including time to reach and duration at various dose levels, were also assessed.

RESULTS

A total of 205 patients were enrolled (58.0 ± 13.27 years; 73.7% male; 34.1% aged ≥ 65 years, baseline N-terminal pro-B-type natriuretic peptide (NT-proBNP) 2490.1 pg/mL). Left ventricular ejection fraction (LVEF) < 30% was observed in 48.8% patients, 24.9% were in New York Heart Association (NYHA) class III. WHF events included recent HF hospitalization within < 7 days (10.7%) or 7 days-3 months (30.2%). Common background therapies included β-blockers (84.9%), mineralocorticoids receptor antagonist (MRAs) (80.5%), sodium-glucose cotransporter 2 (SGLT2) inhibitors (75.6%), and angiotensin receptor-neprilysin inhibitor (ARNI) (52.7%), with 66.3% receiving triple HF therapy. Vericiguat target dose (10 mg) was achieved by 91.1% of patients.

CONCLUSION

This study enrolled high-risk patients with recent decompensation event consistent with the VICTORIA trial. The usage of standard of care (SoC) was as per current clinical practice in HF; VERINA enrolled 52.7% on ARNI compared to 14.5% in VICTORIA and 75.6% on SGLT2i compared to 2% in VICTORIA. Safety data did not reveal any new safety signals or adverse trends in the interim analysis.

TRIAL REGISTRATION: Clinical Trials Registry of India (CTRI/2022/11/047636).

Для цитирования: Abdulakutty Jabir, Abhyankar Atul, Seth Sandeep, Sharma Kamal, Aggarwal Rakesh Kumar, Bhalani Nirav, Vijan Vinod, Bansal Sandeep, Jain Rajendra Kumar Premchand, Banerjee Suvro, Chopra V K, Oomman Abraham, Kahale Pravin, Sodhi Priyanka, Gawde Ashish. Study Design and Baseline Characteristics of the VERINA Study: Phase IV Evidence of Vericiguat for Worsening Heart Failure Management.. Cardiology and therapy. 2025. DOI: 10.1007/s40119-025-00442-4.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.